Eli Lilly Enters R&D and Licensing Deal with Haisco, Up to $3 Billion in Milestones
Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment
Positive
Importance
7
Price
$1,096.15
Mkt Cap
$1.041T
52W Low
$623.78
52W High
$1,149.1
52W Position
76% above low
Off High
4.6% below high
Rel. Volume
1.5× avg
Market data snapshot near publication time
LLY sits 76% above its 52-week low of $623.78.
Summary
Eli Lilly has signed a licensing and R&D collaboration agreement with Haisco Pharmaceutical. The deal includes up to $87 million in upfront and near-term payments to Haisco, with potential for an additional $3.0 billion in subsequent milestone payments. This expands Eli Lilly's research pipeline, adding a new development program.
At the time of this announcement, LLY was trading at $1,096.15 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1T. The 52-week trading range was $623.78 to $1,149.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.
Price Chart
LLY - Latest Insights
LLY
Oct 02, 2026, 3:05 PM EDT
Price at Filing:
$1,147.30
Real-time Price:
$1,143.60
Change:
-$3.70 (-0.32%)
Market Cap:
$1.076T
LLY
Oct 01, 2026, 7:01 AM EDT
Price at Filing:
$1,158.84
Real-time Price:
$1,143.60
Change:
-$15.24 (-1%)
Market Cap:
$1.076T
LLY
Sep 30, 2026, 6:29 PM EDT
Price at Filing:
$1,162.58
Real-time Price:
$1,143.60
Change:
-$18.97 (-2%)
Market Cap:
$1.076T
LLY
Sep 30, 2026, 10:15 AM EDT
Price at Filing:
$1,188.91
Real-time Price:
$1,143.60
Change:
-$45.30 (-4%)
Market Cap:
$1.076T
LLY
Sep 29, 2026, 8:01 AM EDT
Price at Filing:
$1,186.46
Real-time Price:
$1,143.60
Change:
-$42.86 (-4%)
Market Cap:
$1.076T